Lp(a) and Heart Disease 2026: The Genetic Risk Factor Statins Cannot Touch and the New Wave of Therapies That Could Change Cardiology

There is a single number in your blood that most adult Americans have never had measured. It is not LDL. It is not triglycerides. It is not C reactive protein. It is lipoprotein little a, written as Lp(a), and roughly one in five people on Earth carries levels high enough to triple or quadruple their lifetime risk of heart attack and aortic valve disease.

Presented By Our Partners

For sixty years, that fact was a clinical dead end. The level was knowable. It was not modifiable. Statins do not lower it. Diet does not lower it. Exercise does not lower it. The most powerful LDL drugs in medicine, including PCSK9 inhibitors like evolocumab and alirocumab, only blunt it modestly. Cardiologists called it the silent number, and the standard of care for elevated Lp(a) became a careful tightening of every other risk factor while accepting the underlying genetic burden as immovable.

That is changing. In 2026, four investigational therapies, three injected and one oral, are completing or running pivotal Phase 3 outcomes trials that aim to lower Lp(a) by 80 to 95 percent and prove that doing so prevents heart attacks, strokes, and aortic valve replacement. If the readouts confirm the mechanism, Lp(a) will become the first genetically encoded cardiovascular risk factor that medicine has learned to neutralize at the source.

Here is what the science says, what the trials are testing, and what to do in the meantime.

What Lp(a) Actually Is, in Plain English

Lp(a) is a hybrid molecule. At its core sits a low density lipoprotein particle, the same kind of cholesterol carrier that statins are designed to reduce. Wrapped around it is a second protein, apolipoprotein(a), often abbreviated apo(a), which is tethered to the LDL by a single disulfide bond. The combination behaves like LDL on steroids. It carries the same atherogenic cargo, but its second protein component happens to be structurally homologous to plasminogen, the body’s master clot dissolver. That homology means Lp(a) can interfere with normal fibrinolysis, the process by which the body breaks down small clots before they grow dangerous. To round out its biology, Lp(a) preferentially binds and shuttles oxidized phospholipids, a class of pro inflammatory lipids implicated in plaque rupture.

In one molecule, you get atherogenesis, thrombosis, and inflammation. That is why elevated Lp(a) raises risk across the entire spectrum of atherosclerotic cardiovascular disease, not only classical coronary artery disease. It also accelerates calcific aortic valve stenosis, which is now the most common heart valve disease in older adults and the leading reason for valve replacement worldwide.

Lp(a) was first described in 1963 by the Norwegian geneticist Kåre Berg, who noticed an extra band on serum lipoprotein gels in a subset of healthy adults. Its production is controlled by the LPA gene on chromosome 6q26 to q27. The gene contains a remarkable polymorphic region, the kringle IV type 2 repeat, where the number of repeats determines both the size of the apo(a) protein and, inversely, plasma Lp(a) levels. People with fewer repeats produce smaller, more abundant apo(a), and tend to run high. People with more repeats produce larger, less abundant apo(a), and run low. Twin and family studies, summarized in a 2022 European Heart Journal consensus statement led by Florian Kronenberg of the Medical University of Innsbruck, place the heritability of Lp(a) at 70 to 90 percent. Levels are essentially set at birth, stable across the lifespan, and largely indifferent to lifestyle.

That genetic stability is what turned Lp(a) into a powerful natural experiment, and a textbook target for Mendelian randomization. Researchers can ask: do people who happen to inherit lower Lp(a) variants have less cardiovascular disease? The answer, replicated across more than a dozen large cohorts, is yes, and the size of the effect is not subtle.

What the Numbers Say

A 2009 Mendelian randomization analysis from the Copenhagen General Population Study, led by Børge Nordestgaard, established the modern dose response curve. A 2018 meta analysis in JAMA Cardiology and a 2022 update in the European Heart Journal refined the estimates. Per each 50 mg/dL increase in plasma Lp(a), the risk of coronary heart disease roughly doubles, and the risk of aortic valve stenosis roughly triples. The relationship is continuous, dose dependent, and starts well below the conventional 50 mg/dL threshold for elevated Lp(a). The Lp(a) HERITAGE registry, the largest contemporary observational dataset, reported that adults with Lp(a) above 70 mg/dL carry a hazard ratio for major adverse cardiovascular events of approximately 1.7 compared with adults below 30 mg/dL, even after adjustment for LDL, blood pressure, smoking, and diabetes.

The clinical implication is significant. The European Society of Cardiology, the American Heart Association, and the National Lipid Association now recommend testing Lp(a) at least once in adulthood, ideally between ages eighteen and thirty, and using the result to inform the intensity of LDL lowering, blood pressure control, and antithrombotic decisions. The 2024 American Heart Association scientific statement on Lp(a) framed the message bluntly: Lp(a) is one of the most important inherited cardiovascular risk factors, and its measurement is one of the most underused tests in preventive cardiology.

Globally, an estimated 1.4 billion people carry an Lp(a) level above 50 mg/dL, the threshold conventionally defined as elevated. Prevalence is highest in people of South Asian and African ancestry, where median levels run substantially higher than in European populations, and lowest in East Asian populations. In the United States, roughly twenty percent of the adult population is affected. The disease burden, expressed in cardiovascular events attributable to elevated Lp(a), is on the order of magnitude of the burden attributable to elevated LDL.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Why Statins Do Not Help

Statins lower LDL cholesterol by upregulating hepatic LDL receptors. This works because most LDL particles are recycled through that receptor pathway. Lp(a) is different. It is not predominantly cleared through the LDL receptor. It is produced by the liver as an intact assembled particle, with the apo(a) component binding to apoB on a nearly fully formed LDL particle in the hepatic space of Disse. Statins, by some studies, even nudge Lp(a) slightly upward, likely through modest compensatory increases in LPA gene expression. The net result is that the most prescribed drug class in cardiovascular medicine does almost nothing to the most heritable cardiovascular lipid.

PCSK9 inhibitors lower Lp(a) by 20 to 30 percent on average, a meaningful but insufficient effect for someone at the high end of the distribution. Niacin lowers Lp(a) by 20 to 30 percent as well, but the AIM HIGH and HPS2 THRIVE outcomes trials failed to show clinical benefit and produced safety concerns that ended its routine use. Lipoprotein apheresis, a mechanical filtration of plasma, can lower Lp(a) acutely by 60 to 70 percent and is approved in Germany and select European countries for selected patients with progressive atherosclerosis despite optimal medical therapy, but it is impractical, expensive, and not scalable.

Until 2026, that was the state of the art.

The 2026 Trial Wave

Four programs are now in advanced clinical development, three of them in Phase 3 outcomes trials with mortality, myocardial infarction, stroke, and coronary revascularization as primary endpoints. Together they represent the most concentrated assault on a single cardiovascular risk factor since the statin trials of the 1990s.

Pelacarsen

Pelacarsen, developed by Novartis after acquisition from Akcea and Ionis, is an antisense oligonucleotide conjugated to N acetylgalactosamine, a sugar known as GalNAc, which targets the drug to hepatocytes through the asialoglycoprotein receptor. It binds and degrades the messenger RNA for apo(a), the rate limiting protein in Lp(a) assembly. In Phase 2 work led by Sotirios Tsimikas at the University of California San Diego and reported in the New England Journal of Medicine in 2020, monthly subcutaneous pelacarsen lowered Lp(a) by approximately 80 percent. Lp(a) HORIZON, the Phase 3 cardiovascular outcomes trial, enrolled more than 8,000 adults with established atherosclerotic disease and elevated Lp(a). The primary endpoint is the time to first major adverse cardiovascular event. Topline results have been one of the most anticipated readouts in cardiology and were initially expected in 2025, with the most recent guidance pointing toward 2026.

Olpasiran

Olpasiran, developed by Amgen, is a small interfering RNA, or siRNA, also GalNAc conjugated. It works by recruiting the RNA induced silencing complex to cleave the apo(a) messenger RNA. The OCEAN(a) DOSE Phase 2 trial, published in the New England Journal of Medicine in 2022 and led by Steven Nissen at the Cleveland Clinic, found that quarterly subcutaneous dosing reduced Lp(a) by 95 percent or more from baseline. The OCEAN(a) Outcomes Phase 3 trial extended the program to 6,000 patients with established cardiovascular disease and is expected to complete enrollment in 2026.

Lepodisiran

Lepodisiran, developed by Eli Lilly, is also a GalNAc conjugated siRNA, distinguished by its remarkably long duration of action. Phase 1 results published in JAMA in 2023 showed that a single subcutaneous dose lowered Lp(a) by more than 90 percent and that the effect persisted for nearly a year. ACCLAIM Lp(a), the Phase 3 outcomes trial, is enrolling adults at high cardiovascular risk and testing dosing as infrequent as every six to twelve months. If the durability holds in a larger population, lepodisiran would offer the simplest dosing regimen of any cardiovascular drug ever marketed.

Muvalaplin

Muvalaplin, also from Eli Lilly, takes an entirely different approach. It is the first oral Lp(a) lowering drug. Rather than knocking down apo(a) production, muvalaplin binds the kringle IV type 7 and 8 domains of apo(a) and blocks the noncovalent step of Lp(a) assembly, the docking of apo(a) onto apoB. KRAKEN, the Phase 2 trial published in JAMA in 2024 and led by Stephen Nicholls at Monash University, reported Lp(a) reductions of up to 85 percent with daily oral dosing. The next stage of clinical work, including a planned Phase 3 outcomes program, is progressing in 2026.

Three injectables and one pill, four shots on goal, all aimed at the same target. The cardiology community is already preparing guideline frameworks for what the post readout world will look like.

Testing and What to Do Now

For now, Lp(a) is measured by a standard immunoassay, ideally reported in nmol/L, with the threshold of concern around 125 nmol/L, equivalent to roughly 50 mg/dL on the older mass based assay. Because Lp(a) levels are stable across the adult lifespan, a single measurement is generally sufficient for life. Most major preventive cardiology guidelines now recommend universal screening at least once in adulthood. In practice, the test is widely available, inexpensive, and rarely ordered. A 2024 analysis of the All of Us research program reported that fewer than three percent of participants with electronic health record data had ever had an Lp(a) level checked.

If your Lp(a) is elevated, current management focuses on aggressive control of every modifiable cardiovascular risk factor. That means a target LDL meaningfully lower than what would be considered acceptable in a person without elevated Lp(a), often below 70 mg/dL and sometimes below 55 mg/dL for those with established disease, achieved with high intensity statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors as needed. It means tight blood pressure control, ideally below 120 over 80. It means metabolic health, weight management, and smoking cessation. It means careful consideration of low dose aspirin in primary prevention, since the prothrombotic component of Lp(a) interacts with platelet biology, although the aspirin question remains an active area of trial work.

Lifestyle does not lower Lp(a) directly. It lowers everything else, which matters more when Lp(a) is high. Cardiorespiratory fitness, expressed in VO2 max, is the single most powerful modifiable cardiovascular risk factor in observational studies. People with elevated Lp(a) and high VO2 max have outcomes much closer to the general population than people with elevated Lp(a) and low fitness. Sleep regularity, blood pressure variability, glycemic control, visceral adiposity, and cardiorespiratory fitness are the levers that move when the genetic lever cannot.

The Broader Story

Lp(a) is also a test case for a deeper shift underway in preventive cardiology. For most of the last fifty years, cardiovascular risk reduction has been built on probabilistic population averages. We treat LDL because lowering LDL across a population reduces events. We treat blood pressure because lowering blood pressure across a population reduces events. The patient sitting in front of the clinician was an instance of an average. Genetic risk scores, polygenic risk scores, and single locus genetic markers like LPA are pulling cardiology toward the opposite stance. The patient is not an instance of an average. The patient is a particular biochemical reality, with a specific inherited burden, who needs a specific intervention.

That shift has implications well beyond Lp(a). The same mRNA degrading antisense and siRNA platforms that are now being deployed against apo(a) are being tested against ANGPTL3 in extreme hypercholesterolemia, against PCSK9 itself for durable LDL lowering, and against APOC3 in severe hypertriglyceridemia. Verve Therapeutics, founded by Sekar Kathiresan, is pursuing in vivo CRISPR base editing of PCSK9 and other targets, an approach that aims to make a one time treatment produce a lifelong effect. The Lp(a) trials, if they read out positive, will validate the entire genetic medicine playbook in cardiology.

What This Means For You

If you have a personal or family history of early heart attack, stroke, peripheral artery disease, or aortic valve disease, ask your physician for an Lp(a) test. The cost is minimal. The information is for life. If you have ever been told that your cholesterol panel looks fine but you have a striking family history of cardiovascular disease, especially a parent or sibling diagnosed before age sixty, Lp(a) is the most likely explanation that nobody has looked for.

If your Lp(a) is normal, you can move on. Levels do not change meaningfully across adulthood, so retesting is rarely useful. If your Lp(a) is elevated, you have actionable information. You are not powerless. Aggressive management of every other cardiovascular risk factor materially changes outcomes, and the next several years are likely to bring the first targeted therapies in the history of cardiovascular medicine that work directly on the inherited risk itself. Talk with your clinician about the timeline of pelacarsen, olpasiran, lepodisiran, and muvalaplin. Ask whether you should be considered for ongoing trials, several of which are still enrolling at major academic medical centers. Use the time between now and approval to optimize the rest of your cardiovascular profile, especially LDL, blood pressure, glycemic control, sleep, and cardiorespiratory fitness.

This is a story about a long ignored number in human blood, the genetic luck that determines its level, and a small group of cardiologists, geneticists, and trialists who refused to accept that anything in the body should be considered immovable. The full answer is not here yet. The trials still need to read out. The drugs still need to be approved. The clinical workflows still need to catch up. But the era in which Lp(a) was a useful piece of prognostic information and nothing else is ending.

For the first time in sixty years, the silent number is about to start talking back.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.